摘要
地诺单抗是一种针对骨巨细胞瘤(GCTB)基质细胞核因子-κB受体活化蛋白(RANK)配体的单克隆抗体,可抑制肿瘤的溶骨性破坏。目前一系列研究已经证明,地诺单抗在扩大病灶刮除术前新辅助降期方面效果良好,对难以手术患者可以行地诺单抗姑息治疗。但亦有研究表明,相比单纯行病灶刮除术,地诺单抗联合刮除术在术后更可能会局部复发;地诺单抗对肿瘤基质细胞具有一定抑制作用,但不具有杀灭作用;地诺单抗治疗后肿瘤组织出现恶性细胞特征;在地诺单抗给药期间发生恶性肿瘤转变,具体原因还有待进一步研究。现对地诺单抗在GCTB中的应用研究进展进行综述。
Denosumab is a monoclonal antibody against nuclear factor-κB receptor-activated protein(RANK)ligand in giant cell tumor of bone(GCTB)stromal cells,which can inhibit the osteolytic destruction of tumors.At present,a series of studies have proved that denosumab has a good effect in expanding neoadjuvant downstage before curettage,and palliative treatment of denosumab can be used for patients with difficult surgery.However,some studies have shown that compared with simple curettage,denosumab combined with curettage is more likely to cause local recurrence after surgery;denosumab has a certain inhibitory effect on tumor stromal cells,but does not kill them;malignant cell characteristics appear in tumor tissue after denosumab treatment;malignant tumor transformation occurs during the administration of denosumab,and the specific reasons need to be further studied.This article application research progress of denosumab in GCTB is now reviewed.
作者
田齐
田征
陈江涛
TIAN Qi;TIAN Zheng;CHEN Jiangtao;Sakarie Mustafe Hidig(Department of Bone Tumor Surgery,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China)
出处
《陕西医学杂志》
CAS
2021年第6期763-765,F0003,共4页
Shaanxi Medical Journal
基金
新疆维吾尔自治区自然科学基金资助项目(2017D01C286)。
